Electrochemiluminescence immunosensor based on signal probe CuFeS<sub>2</sub> quantum Dots for ultrasensitive detection of cyclin D1
Anzi Yang,Xiaoxia Huangfu,Lixiao Liu,Wen Luo,Wenbo Zhao,Jun Yin
DOI: https://doi.org/10.1016/j.jelechem.2020.114269
IF: 4.598
2020-01-01
Journal of Electroanalytical Chemistry
Abstract:Biomedical detection needs to develop more detection methods and reagents. CuFeS2, an I-III-IV ternary semiconductor material, has attracted great interest of researchers because of its optical, electrical, low toxicity and controllable chemical synthesis. Here, we synthesized CuFeS2 quantumdots (QDs) with hot-injectionmethod and their ECL behaviors were investigated for the first time, involving the co-reactant anode/cathode ECL emission and the related ECL mechanism. Moreover, a novel ECL immunosensor based on CuFeS2 QDs for the ultrasensitive detection of Cyclin D1 (CCND1) was designed and prepared. CuFeS2 QDs with uniform size and excellent optical properties were used as ECL emitters and Carboxyl Fe3O4 magnetic beads (MB) were utilized for magnetic separation of CCND1 from MCF-7 cells treated by sophora frevescens. In addition, reduced graphene oxide (rGO) andAuNPs by electrodeposition not only provided plentiful active sites for the immobilization of anti-CCND1 (primary antibody, Ab(1)), but also enhanced the conductivity of the electrode. Results indicated that under the optimal condition, the ECL signal was proportional to the logarithmic of CCND1 concentration in the linear range from 40 fg/mL to 0.8 mu g/mL with a detection limit of 15.8 fg/mL. Further, the good reproducibility, stability and selectivity of the as-prepared ECL immunosensor were also proved. Significantly, the anticancer effect of sophora frevescens on MCF-7 cells was investigated through quantitative analysis of overexpression of CCND1, which was related to proliferation of cancer cells. This research indicated the ECL immunosensor we suggested could offer great potential for the follow-up research in clinical diagnosis and anticancer drug screening.